Mabpharm (HKSE:02181) Debt-to-Revenue : 3.01 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Mabpharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$137.01 Mil. Mabpharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$147.46 Mil. Mabpharm's annualized Revenue for the quarter that ended in Dec. 2023 was HK$94.37 Mil. Mabpharm's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 3.01.

Mabpharm Debt-to-Revenue Historical Data

The historical data trend for Mabpharm's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Debt-to-Revenue Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

0.55

2.26

2.98

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial								13.97	2.20	2.33	1.68	3.01

Competitive Comparison of Mabpharm's Debt-to-Revenue

For the Biotechnology subindustry, Mabpharm's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mabpharm's Debt-to-Revenue falls into.

Mabpharm Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Mabpharm's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(137.005	+	147.458)	/	95.335
	=	2.98

Mabpharm's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(137.005	+	147.458)	/	94.374
	=	3.01

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Mabpharm Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mabpharm's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines